E
Pharmadrug Inc.
PHRX
CNSX
E
Sell
2/10/2025Downgrade
Pharmadrug Inc. (PHRX) was downgraded to E from E+ on 2/10/2025 due to a significant decline in the solvency index, growth index and total return index. EBIT declined 2,082.35% from -$1.7 to -$37.1, the quick ratio declined from 0.1 to 0.07, and earnings per share declined from -$0.001 to -$0.0013.
Pharmadrug Inc. (PHRX) was downgraded to E from E+ on 2/10/2025 due to a significant decline in the solvency index, growth index and total return index. EBIT declined 2,082.35% from -$1.7 to -$37.1, the quick ratio declined from 0.1 to 0.07, and earnings per share declined from -$0.001 to -$0.0013.
E
Sell
5/8/2023Downgrade
Pharmadrug Inc. (PHRX) was downgraded to E+ from D- on 5/8/2023 due to a noticeable decline in the volatility index and total return index.
Pharmadrug Inc. (PHRX) was downgraded to E+ from D- on 5/8/2023 due to a noticeable decline in the volatility index and total return index.
D
Sell
3/14/2023Downgrade
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 03/14/2023.
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 03/14/2023.
D
Sell
2/9/2023Upgraded
Pharmadrug Inc. (PHRX) was upgraded to D from E+ on 02/09/2023.
Pharmadrug Inc. (PHRX) was upgraded to D from E+ on 02/09/2023.
E
Sell
2/8/2023Downgrade
Pharmadrug Inc. (PHRX) was downgraded to E+ from D on 02/08/2023.
Pharmadrug Inc. (PHRX) was downgraded to E+ from D on 02/08/2023.
D
Sell
1/4/2023Upgraded
Pharmadrug Inc. (PHRX) was upgraded to D from D- on 1/4/2023 due to an increase in the volatility index and total return index.
Pharmadrug Inc. (PHRX) was upgraded to D from D- on 1/4/2023 due to an increase in the volatility index and total return index.
D
Sell
12/15/2022Downgrade
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 12/15/2022 due to a decline in the volatility index.
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 12/15/2022 due to a decline in the volatility index.
D
Sell
11/29/2022Upgraded
Pharmadrug Inc. (PHRX) was upgraded to D from E+ on 11/29/2022 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0121 to -$0.0018, operating cash flow increased 49.11% from -$485 to -$246.8, and EBIT increased 1.46% from -$418.4 to -$412.3.
Pharmadrug Inc. (PHRX) was upgraded to D from E+ on 11/29/2022 due to a large increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.0121 to -$0.0018, operating cash flow increased 49.11% from -$485 to -$246.8, and EBIT increased 1.46% from -$418.4 to -$412.3.
E
Sell
11/16/2022Downgrade
Pharmadrug Inc. (PHRX) was downgraded to E+ from D- on 11/16/2022 due to a decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0047 to -$0.0121, the quick ratio declined from 0.71 to 0.21, and debt to equity increased from 0.05 to 0.08.
Pharmadrug Inc. (PHRX) was downgraded to E+ from D- on 11/16/2022 due to a decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.0047 to -$0.0121, the quick ratio declined from 0.71 to 0.21, and debt to equity increased from 0.05 to 0.08.
D
Sell
8/22/2022Downgrade
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 8/22/2022 due to a major decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0033 to -$0.0047, EBIT declined 21.14% from -$1.02M to -$1.24M, and operating cash flow declined 10.31% from -$896.5 to -$988.9.
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 8/22/2022 due to a major decline in the total return index, volatility index and growth index. Earnings per share declined from -$0.0033 to -$0.0047, EBIT declined 21.14% from -$1.02M to -$1.24M, and operating cash flow declined 10.31% from -$896.5 to -$988.9.
D
Sell
5/4/2022Upgraded
Pharmadrug Inc. (PHRX) was upgraded to D from D- on 05/04/2022.
Pharmadrug Inc. (PHRX) was upgraded to D from D- on 05/04/2022.
D
Sell
4/20/2022Downgrade
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, total return index and valuation index. The quick ratio declined from 8.19 to 6.44.
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 4/20/2022 due to a decline in the solvency index, total return index and valuation index. The quick ratio declined from 8.19 to 6.44.
D
Sell
11/23/2021Upgraded
Pharmadrug Inc. (PHRX) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
Pharmadrug Inc. (PHRX) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index.
D
Sell
11/8/2021Downgrade
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Pharmadrug Inc. (PHRX) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
12/1/2020Upgraded
Pharmadrug Inc. (BUZZ) was upgraded to D from D- on 12/1/2020 due to a large increase in the growth index and solvency index. The quick ratio increased from 0.57 to 1.94, earnings per share increased from -$0.0116 to -$0.0038, and debt to equity declined from 0.46 to 0.18.
Pharmadrug Inc. (BUZZ) was upgraded to D from D- on 12/1/2020 due to a large increase in the growth index and solvency index. The quick ratio increased from 0.57 to 1.94, earnings per share increased from -$0.0116 to -$0.0038, and debt to equity declined from 0.46 to 0.18.
D
Sell
8/28/2020Downgrade
Pharmadrug Inc. (BUZZ) was downgraded to D- from D on 8/28/2020 due to a large decline in the growth index and total return index. Earnings per share declined from -$0.0012 to -$0.0123, operating cash flow declined 189.87% from -$111.5 to -$323.2, and EBIT declined 111.67% from -$443.2 to -$938.1.
Pharmadrug Inc. (BUZZ) was downgraded to D- from D on 8/28/2020 due to a large decline in the growth index and total return index. Earnings per share declined from -$0.0012 to -$0.0123, operating cash flow declined 189.87% from -$111.5 to -$323.2, and EBIT declined 111.67% from -$443.2 to -$938.1.
D
Sell
7/14/2020Upgraded
Pharmadrug Inc. (BUZZ) was upgraded to D from D- on 7/14/2020 due to a major increase in the growth index, total return index and solvency index. Total revenue increased 363.07% from $28.7 to $132.9, earnings per share increased from -$0.0318 to -$0.0022, and EBIT increased 80.37% from -$2.26M to -$443.2.
Pharmadrug Inc. (BUZZ) was upgraded to D from D- on 7/14/2020 due to a major increase in the growth index, total return index and solvency index. Total revenue increased 363.07% from $28.7 to $132.9, earnings per share increased from -$0.0318 to -$0.0022, and EBIT increased 80.37% from -$2.26M to -$443.2.
D
Sell
6/17/2020Downgrade
Pharmadrug Inc. (BUZZ) was downgraded to D- from D on 6/17/2020 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.004 to -$0.0338, EBIT declined 396.99% from -$275.6 to -$1.37M, and debt to equity increased from 0.41 to 1.01.
Pharmadrug Inc. (BUZZ) was downgraded to D- from D on 6/17/2020 due to a large decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.004 to -$0.0338, EBIT declined 396.99% from -$275.6 to -$1.37M, and debt to equity increased from 0.41 to 1.01.
D
Sell
5/19/2020Upgraded
Pharmadrug Inc. (BUZZ) was upgraded to D from D- on 5/19/2020 due to an increase in the volatility index, total return index and solvency index.
Pharmadrug Inc. (BUZZ) was upgraded to D from D- on 5/19/2020 due to an increase in the volatility index, total return index and solvency index.
D
Sell
11/29/2019Upgraded
Pharmadrug Inc. (BUZZ) was upgraded to D- from E+ on 11/29/2019 due to an increase in the growth index, efficiency index and total return index. Operating cash flow increased 81.77% from -$1.33M to -$243, earnings per share increased from -$0.0148 to -$0.0045, and net income increased 68.15% from -$1.04M to -$330.4.
Pharmadrug Inc. (BUZZ) was upgraded to D- from E+ on 11/29/2019 due to an increase in the growth index, efficiency index and total return index. Operating cash flow increased 81.77% from -$1.33M to -$243, earnings per share increased from -$0.0148 to -$0.0045, and net income increased 68.15% from -$1.04M to -$330.4.
E
Sell
11/20/2019Downgrade
Pharmadrug Inc. (BUZZ) was downgraded to E+ from D- on 11/20/2019 due to a decline in the total return index and volatility index.
Pharmadrug Inc. (BUZZ) was downgraded to E+ from D- on 11/20/2019 due to a decline in the total return index and volatility index.
D
Sell
11/5/2019Upgraded
Pharmadrug Inc. (BUZZ) was upgraded to D- from E+ on 11/5/2019 due to an increase in the volatility index and total return index.
Pharmadrug Inc. (BUZZ) was upgraded to D- from E+ on 11/5/2019 due to an increase in the volatility index and total return index.
E
Sell
10/7/2019Downgrade
Aura Health Inc. (BUZZ) was downgraded to E+ from D- on 10/7/2019 due to a decline in the volatility index, total return index and efficiency index. Net income declined 58.56% from -$654.2 to -$1.04M.
Aura Health Inc. (BUZZ) was downgraded to E+ from D- on 10/7/2019 due to a decline in the volatility index, total return index and efficiency index. Net income declined 58.56% from -$654.2 to -$1.04M.
D
Sell
5/1/2019Upgraded
Aura Health Inc. (BUZZ) was upgraded to D- from E on 5/1/2019 due to an increase in the total return index and volatility index.
Aura Health Inc. (BUZZ) was upgraded to D- from E on 5/1/2019 due to an increase in the total return index and volatility index.
E
Sell
2/1/2019Upgraded
Aura Health Inc. (BUZZ) was upgraded to E from E- on 2/1/2019 due to an increase in the volatility index.
Aura Health Inc. (BUZZ) was upgraded to E from E- on 2/1/2019 due to an increase in the volatility index.
E
Sell
11/29/2018None
Pharmadrug Inc. (PHRX) was downgraded to E- from U on 11/29/2018.
Pharmadrug Inc. (PHRX) was downgraded to E- from U on 11/29/2018.
